Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 5% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares rose 5% during trading on Tuesday . The stock traded as high as $26.80 and last traded at $26.71. Approximately 62,092 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 196,014 shares. The stock had previously closed at $25.43.

Analyst Ratings Changes

A number of research firms have weighed in on DNTH. Oppenheimer began coverage on Dianthus Therapeutics in a report on Thursday, October 3rd. They set an “outperform” rating and a $48.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Cantor Fitzgerald initiated coverage on Dianthus Therapeutics in a research report on Thursday, June 27th. They set an “overweight” rating for the company. Robert W. Baird started coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price on the stock. Finally, Baird R W upgraded shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Friday, July 26th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $45.13.

Dianthus Therapeutics Trading Up 8.3 %

The company has a market cap of $808.27 million, a P/E ratio of -4.72 and a beta of 1.85. The stock’s 50 day moving average is $27.70 and its 200-day moving average is $26.07.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The firm had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $0.63 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.28 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of Dianthus Therapeutics during the second quarter valued at $112,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $236,000. WINTON GROUP Ltd bought a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $265,000. Point72 DIFC Ltd purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $334,000. Finally, Virtu Financial LLC bought a new position in Dianthus Therapeutics during the first quarter valued at approximately $390,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.